ArticleMolecular cancer therapeutics2020

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity.

Zeliang Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.